TippingPoint Biosciences is dedicated to creating new approaches to treat diseases of genome packaging such as hard-to-treat cancers and improve the quality of life of the patients. Launched in 2023, TippingPoint Biosciences is an SF-based therapeutic company with a mission to improve and save the lives of patients who suffer from diseases with high unmet needs. Co-founded by Dr. Laura Hsieh, American Cancer Society Fellow, and Dr. Geeta J. Narlikar, UCSF Professor of Biochemistry and Biophysics and National Academy of Sciences member, TippingPoint Biosciences is a startup that was inspired by the ground-breaking discoveries made in Dr. Narlikar’s laboratory at UCSF. The company has built a new type of drug discovery platform to identify treatments for diseases caused by defects in DNA packaging, which include several hard-to-treat cancers. TippingPoint’s proprietary platform addresses major limitations and challenges seen in the healthcare space by recreating the biological context of
Something looks off?